When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Leucemia mieloide aguda

  • Descripción general
  • Teoría
  • Diagnóstico
  • Manejo
  • Seguimiento
  • Recursos
Последний просмотренный: 19 Jun 2025
Last updated: 03 May 2024

Резюме

Определение

Анамнез и осмотр

Ключевые диагностические факторы

  • palidez
  • equimosis o petequias
Полная информация

Другие диагностические факторы

  • fatiga
  • mareos
  • palpitaciones
  • disnea
  • infecciones o fiebre
  • linfadenopatía
  • hepatoesplenomegalia
  • sangrado mucoso
  • masa cutánea o testicular
  • infiltración cutánea
  • agrandamiento gingival
  • dolor óseo
  • cloromas cutáneos
  • dolor abdominal
Полная информация

Факторы риска

  • mayores de 65 años
  • tratamiento previo con quimioterapia
  • trastornos hematológicos previos
  • afecciones genéticas heredadas
  • anomalías cromosómicas constitucionales
  • exposición a la radiación
  • exposición al benceno
  • exposiciones ambientales
  • sexo masculino
Полная информация

Диагностические исследования

Исследования, которые показаны в первую очередь

  • hemograma completo (HC) con diferencial
  • frotis de sangre periférica
  • perfil de coagulación
  • electrolitos séricos y ácido úrico
  • función renal
  • pruebas de función hepática (PFH)
  • lactato deshidrogenasa sérica
  • evaluación de la médula ósea
  • pruebas diagnósticas citogenéticas y moleculares
Полная информация

Исследования, проведение которых нужно рассмотреть

  • punción lumbar
  • tipificación del antígeno leucocitario humano (HLA)
  • radiografía de tórax
  • ecocardiograma
  • ventriculografía con radionúclidos
Полная информация

Алгоритм лечения

Острый

LMA recién diagnosticada: apta para quimioterapia estándar de dosis intensiva

LMA recién diagnosticada: no apta para quimioterapia estándar de dosis intensiva

leucemia promielocítica aguda (LPA) de reciente diagnóstico y sin alto riesgo

leucemia promielocítica aguda (LPA) de alto riesgo recién diagnosticada

ПРОДОЛЖЕНИЕ

remisión completa: LMA

remisión completa: leucemia promielocítica aguda (LPA) de no alto riesgo

remisión completa: leucemia promielocítica aguda de alto riesgo (LPA)

LMA en recidiva o refractaria

leucemia promielocítica aguda (LPA) en recidiva o refractaria

Составители

Авторы

Vijaya Raj Bhatt, MBBS, MS

​Associate Professor

Section Leader, Malignant Hematology

University of Nebraska Medical Center Division of Hematology-Oncology

Nebraska

NE

Раскрытие информации

VRB has participated in a Safety Monitoring Committee for Protagonist Therapeutics. He has received consulting fees from Imugene; research funding (institutional) from Abbvie, Pfizer, Incyte, Jazz, and NMDP; and drug support (institutional) from Chimerix for a trial.

Prajwal Dhakal, MBBS

Clinical Assistant Professor of Internal Medicine-Hematology, Oncology, and Blood and Marrow Transplantation

University of Iowa

Iowa City

IA

Раскрытие информации

PD declares that he has no competing interests.

Выражение благодарностей

Dr Vijaya Raj Bhatt and Dr Prajwal Dhakal would like to gratefully acknowledge Dr Kavita Raj and Dr Priyanka Mehta, previous contributors to this topic.

Раскрытие информации

KR declares that she has no competing interests. PM is an author of a reference cited in this topic.

Рецензенты

Rebecca Connor, MD

Chief Fellow

Section of Hematology and Oncology

Department of Internal Medicine

Wake Forest University Baptist Medical Center

Winston-Salem

NC

Раскрытие информации

RC declares that she has no competing interests.

Roger M. Lyons, MD, FACP

Clinical Professor of Medicine

University of Texas Health Science Center

San Antonio

Cancer Care Network of South Texas

San Antonio

TX

Раскрытие информации

RML declares that he has no competing interests.

Shankaranarayana Paneesha, MD, MRCP, FRCPath

Consultant Haematologist

Department of Haematology and Stem Cell Transplantation

Heartlands Hospital

Birmingham

UK

Раскрытие информации

SP declares that he has no competing interests.

David Marks, MD, MRCP, MRCPath

Professor of Haematology & Stem Cell Transplantation

Department of Molecular and Cellular Medicine

University of Bristol

UK

Раскрытие информации

DM declares that he has no competing interests.

Список литературы

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Основные статьи

Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-77.Полный текст  Аннотация

National Cancer Comprehensive Network. NCCN guidelines: acute myeloid leukemia [internet publication].Полный текст

Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jun;31(6):697-712.Полный текст  Аннотация

Sekeres MA, Guyatt G, Abel G, et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020 Aug 11;4(15):3528-49.Полный текст  Аннотация

Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019 Apr 11;133(15):1630-43.Полный текст  Аннотация

Статьи, указанные как источники

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Использование этого контента попадает под действие нашего заявления об отказе от ответственности